Fullerene C60 and ascorbic acid protect cultured chromaffin cells against levodopa toxicity

Journal of Neuroscience Research

Volumn 71, Issue 1, 2003, Pages 121-126

  Corona Morales, Aleph A ^a   Castell, Andrés ^a   Escobar, Alfonso ^b   Drucker Colín, René ^b   Zhang, Limei ^a  

^a UNIVERSIDAD NACIONAL AUTÓNOMA DE MÉXICO   (Mexico)

^b UNIVERSIDAD NACIONAL AUTÓNOMA DE MÉXICO   (Mexico)

Author keywords

Apoptosis; Neurotoxicity; Parkinson's disease; Tyrosine hydroxylase, TUNEL

Indexed keywords

ASCORBIC ACID; FULLERENE DERIVATIVE; LEVODOPA; TRIS(DICARBOXYMETHYLENE)FULLERENE C3; TYROSINE 3 MONOOXYGENASE; UNCLASSIFIED DRUG; ANTIOXIDANT; DOPAMINE RECEPTOR STIMULATING AGENT; FULLERENE C60; PROTECTIVE AGENT;

ANIMAL CELL; ANTIOXIDANT ACTIVITY; APOPTOSIS; ARTICLE; CELL DEATH; CELL PROTECTION; CELL SURVIVAL; CELL TRANSPLANTATION; CHROMAFFIN CELL; NERVE CELL CULTURE; NEUROTOXICITY; NICK END LABELING; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; ANIMAL; COMPARATIVE STUDY; DRUG EFFECT; DRUG INTERACTION; IMMUNOHISTOCHEMISTRY; METABOLISM; METHODOLOGY; OXIDATIVE STRESS; PHYSIOLOGY; RAT; WISTAR RAT;

ANIMALS; ANTIOXIDANTS; APOPTOSIS; ASCORBIC ACID; CHROMAFFIN CELLS; DOPAMINE AGENTS; DRUG INTERACTIONS; FULLERENES; IMMUNOHISTOCHEMISTRY; IN SITU NICK-END LABELING; LEVODOPA; OXIDATIVE STRESS; PROTECTIVE AGENTS; RATS; RATS, WISTAR; TYROSINE 3-MONOOXYGENASE;

EID: 0037209038     PISSN: 03604012     EISSN: None     Source Type: Journal    
DOI: 10.1002/jnr.10456     Document Type: Article

References (25)

1. Ajayan PM, Terrones M, de la Guardia A, Huc V, Grobert N, Wei BQ, Lezec H, Ramanath G, Ebbesen TW. 2002. Nanotubes in a flash ignition and reconstruction. Science 296:705.
2. Basma AN, Morris EJ, Niclas WJ, Gella HM. 1995. L-DOPA cytotoxicity to PC 12 cells in culture is via its auto-oxidation. J Neurochem 64:825-832.
3. Blum D, Torch S, Lambeng N, Nissou M, Benabid AL, Sadoul R, Verna JM. 2001. Molecular pathways involved in the neurotoxicity of 6-OHDA, dopamine and MPTP: Contribution to the apoptotic theory in Parkinson's disease. Progr Neurobiol 65:135-172.
4. Corona-Morales AA, Castell A, Zhang L. 2000. L-DOPA-induced neurotoxic and apoptotic changes on cultured chromaffin cells. Neuroreport 11:503-506.
5. Dugan LL, Gabrielsen JK, Yu SP, Lin TS, Choi DW. 1996. Buckminster-fullerenol free radical scavengers reduce excitotoxic and apoptotic death of cultured cortical neurons. Neurobiol Dis 3:129-135.
6. Dugan LL, Turensky DM, Du C, Lobner D, Wheeler M, Almli CR, Shen CK, Luh TY, Choi DW, Lin TS. 1997. Carboxyfullerenes as neuroprotective agents. Proc Natl Acad Sci USA 94:9434-9439.
7. Dugan LL, Lovett EG, Quick KL, Lotharius J, Lin TT, O'Malley KL. 2001. Fullerene-based antioxidants and neurodegenerative disorders. Parkinsonism Rel Disord 7:243-246.
8. Dunnett SB, Björklund A, Lindvall O. 2001. Cell therapy in Parkinson's disease - Stop or go? Nat Rev Neurosci 2:365-369.
9. Ganong WF. 2001. Review of Medical Physiology, 20th Ed. San Francisco: McGraw-Hill. p 346-348.
10. Graham DG. 1978. Oxidative pathways for catecholamines in the genesis of neuromelanin and cytotoxic quinones. Mol Pharmacol 14:633-643.
11. Graham DG, Tiffany SM, Bell WR Jr, Gutknecht WF. 1978. Autoxidation versus covalent binding of quinones as the mechanism of toxicity of dopamine, 6-hydroxydopamine, and related compounds toward C1300 neuroblastoma cells in vitro. Mol Pharmacol 14:644-653.
12. Han SK, Mytilineou C, Cohen G. 1996. L-DOPA up-regulates glutathione and protects mesancephalic culture against oxidative stress. J Neurochem 66:501-510.
13. Hirsch EC, Duyckaerts C, Javoy-Agid F, Hauw JJ, Agid Y. 1990. Does adrenal graft enhance recovery of dopaminergic neurons in Parkinson's disease? Ann Neurol 27:676-682.
14. Lang AE. 2000. Surgery for Parkinson disease: A critical evaluation of the state of the art. Arch Neurol 57:1118-1125.
15. Jenner PG, Brin MF. 1998. Levodopa neurotoxicity: Experimental studies versus clinical relevance. Neurology 50(Suppl 6):S39-S43.
16. Kamat JP, Devasagayam TPA, Priyadarsini KI, Mohan H. 2000. Reactive oxygen species mediated membrane damage induced by fullerene derivatives and its possible biological implications. Toxicology 155:55-61.
17. Krinsky NI. 1992. Mechanism of action of biological antioxidants. Proc Soc Exp Biol Med 200:248-254.
18. 60 Buckminsterfullerene. Nature 318:162-163.
19. Madrazo I, Drucker-Colín R, Díaz V, Martínez-Mata J, Torres C, Becerril JJ. 1987. Open microsurgical autograft of adrenal medulla to the right caudate nucleus in two patients with intractable Parkinson's desease. N Engl J Med 316:831-34.
20. Masserano JM, Gong L, Kulaga H, Backer I, Wyatt RJ. 1996. Dopamine induces apoptotic cell death of a catecholaminergic cell line derived from the central nervous system. Mol Pharmacol 50:1309-1315.
21. Pardo B, Mena MA, Casajeros MJ, Paino CL, De Tebenes JG. 1993. Toxic effects of L-DOPA on mesencephalic cell cultures: Protection with antioxidants. Brain Res 682:133-143.
22. Walkinshaw G, Waters CM. 1995. Induction of apoptosis in catecholaminergic PC12 cells by L-DOPA. Implications for the treatment of Parkinson's disease. J Clin Invest 95:2458-2464.
23. Yurek DM, Steece-Collier K, Collier TJ, Sladek JR Jr. 1991. Chronic levodopa impairs the recovery of dopamine agonist-induced rotational behavior following neural grafting. Exp Brain Res 86:97-107.
24. 60 compound on guinea pig isolated myocyte electrical activity and rat chromaffin cell differentiation and proliferation. Fullerene Sci Technol 6:815-825.
25. Zhang L, Castell A, Ávila ME, Drucker-Colín R, Escobar A. 2000. Immunocytochemical, ultrastructural and neurochemical evidences on synaptogenesis and dopamine release of rat chromaffin cells co-cultured with striatal neurons. J Neuropathol Exp Neurol 59:170-174.